Literature DB >> 28338667

Primary photodynamic therapy with verteporfin for small pigmented posterior pole choroidal melanoma.

I D Fabian1, A W Stacey1,2, V Papastefanou1, L Al Harby1, A K Arora1, M S Sagoo1,3, V M L Cohen1.   

Abstract

PurposeThe purpose of the study was to investigate the outcomes of primary photodynamic therapy (PDT) for small pigmented posterior pole choroidal melanoma.Patients and methodsProspective interventional consecutive case series of 15 patients with small pigmented posterior pole choroidal melanoma, who were treated with three sessions of PDT and followed-up thereafter. Risk factors for failure were assessed and outcome measures at presentation were compared to those at last follow-up visit.ResultsTumor control was achieved in 12 (80%) patients in a median follow-up time of 15 months (mean 14, range 8-18). Three patients failed treatment, diagnosed in a median time of 5 months (mean 4, range 3-6), after first PDT. In all failed cases, lesions were 100% pigmented; de novo melanoma rather than transformed nevi and showed a radial growth pattern rather than increased thickness. All failed cases were subsequently successfully treated with radiotherapy. In this cohort, subretinal fluid (SRF) was significantly reduced (P<0.001), vision did not deteriorate (P=0.11) and even improved in patients with subfoveal SRF at presentation (P=0.018), tumor height significantly decreased (P=0.037) and no complications were recorded.ConclusionPrimary PDT was found to be a safe and efficient treatment modality for small pigmented posterior pole choroidal melanoma, achieving short-term tumor control in 80% of patients. PDT offers patients the opportunity to preserve vision by avoiding the retinopathy associated with conventional radiation treatments for choroidal melanoma. However, the long-term local control of these tumors remains uncertain.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28338667      PMCID: PMC5396011          DOI: 10.1038/eye.2017.22

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  21 in total

1.  Treatment of amelanotic choroidal melanoma with photodynamic therapy.

Authors:  William G Campbell; Tanya M Pejnovic
Journal:  Retina       Date:  2012-07       Impact factor: 4.256

2.  [Photodynamic therapy of pigmented choroidal melanomas in rabbits].

Authors:  Likuan Hu; Xinyi Wu; Yipeng Song; Lucy H Y Young; Evangelos S Gragoudas
Journal:  Zhonghua Yan Ke Za Zhi       Date:  2002-08

3.  Primary treatment of choroidal amelanotic melanoma with photodynamic therapy.

Authors:  Mark J Donaldson; Lyndell Lim; C Alex Harper; John Mackenzie; William G Campbell
Journal:  Clin Exp Ophthalmol       Date:  2005-10       Impact factor: 4.207

4.  Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes.

Authors:  Carol L Shields; Minoru Furuta; Archana Thangappan; Saya Nagori; Arman Mashayekhi; David R Lally; Cecilia C Kelly; Danielle S Rudich; Anand V Nagori; Oojwala A Wakade; Sonul Mehta; Lauren Forte; Andrew Long; Elaina F Dellacava; Bonnie Kaplan; Jerry A Shields
Journal:  Arch Ophthalmol       Date:  2009-08

5.  Combination of clinical factors predictive of growth of small choroidal melanocytic tumors.

Authors:  C L Shields; J Cater; J A Shields; A D Singh; M C Santos; C Carvalho
Journal:  Arch Ophthalmol       Date:  2000-03

6.  Photodynamic therapy of pigmented choroidal melanomas of greater than 3-mm thickness.

Authors:  R Y Kim; L K Hu; B S Foster; E S Gragoudas; L H Young
Journal:  Ophthalmology       Date:  1996-12       Impact factor: 12.079

7.  Photodynamic therapy of pigmented choroidal melanomas.

Authors:  V H Gonzalez; L K Hu; P G Theodossiadis; T J Flotte; E S Gragoudas; L H Young
Journal:  Invest Ophthalmol Vis Sci       Date:  1995-04       Impact factor: 4.799

8.  Plaque radiotherapy for juxtapapillary choroidal melanoma: treatment complications and visual outcomes in 650 consecutive cases.

Authors:  Mandeep S Sagoo; Carol L Shields; Jacqueline Emrich; Arman Mashayekhi; Lydia Komarnicky; Jerry A Shields
Journal:  JAMA Ophthalmol       Date:  2014-06       Impact factor: 7.389

9.  Vascular targeting in photodynamic occlusion of subretinal vessels.

Authors:  U Schmidt-Erfurth; T Hasan; E Gragoudas; N Michaud; T J Flotte; R Birngruber
Journal:  Ophthalmology       Date:  1994-12       Impact factor: 12.079

Review 10.  Is observation really appropriate for small choroidal melanomas.

Authors:  J J Augsburger
Journal:  Trans Am Ophthalmol Soc       Date:  1993
View more
  9 in total

1.  Are Risk Factors for Growth of Choroidal Nevi Associated With Malignant Transformation? Assessment With a Validated Genomic Biomarker.

Authors:  J William Harbour; Manuel Paez-Escamilla; Louis Cai; Scott D Walter; James J Augsburger; Zelia M Correa
Journal:  Am J Ophthalmol       Date:  2018-09-07       Impact factor: 5.258

Review 2.  A promising anticancer drug: a photosensitizer based on the porphyrin skeleton.

Authors:  Qizhi Zhang; Jun He; Wenmei Yu; Yanchun Li; Zhenhua Liu; Binning Zhou; Yunmei Liu
Journal:  RSC Med Chem       Date:  2020-02-25

Review 3.  Photodynamic Therapy for Eye Cancer.

Authors:  Paul Rundle
Journal:  Biomedicines       Date:  2017-12-08

Review 4.  Treatment of uveal melanoma: where are we now?

Authors:  Jessica Yang; Daniel K Manson; Brian P Marr; Richard D Carvajal
Journal:  Ther Adv Med Oncol       Date:  2018-02-21       Impact factor: 8.168

Review 5.  Susceptibility and Resistance Mechanisms During Photodynamic Therapy of Melanoma.

Authors:  Xin-Ying Li; Liu-Chang Tan; Li-Wen Dong; Wan-Qi Zhang; Xiao-Xiao Shen; Xiao Lu; Hong Zheng; Yuan-Gang Lu
Journal:  Front Oncol       Date:  2020-05-12       Impact factor: 6.244

Review 6.  New Perspectives for Eye-Sparing Treatment Strategies in Primary Uveal Melanoma.

Authors:  Krzysztof Bilmin; Kamil J Synoradzki; Anna M Czarnecka; Mateusz J Spałek; Tamara Kujawska; Małgorzata Solnik; Piotr Merks; Mario Damiano Toro; Robert Rejdak; Michał Fiedorowicz
Journal:  Cancers (Basel)       Date:  2021-12-28       Impact factor: 6.639

Review 7.  Nanoparticle-Based Drug Delivery Systems for Photodynamic Therapy of Metastatic Melanoma: A Review.

Authors:  Nkune Williams Nkune; Heidi Abrahamse
Journal:  Int J Mol Sci       Date:  2021-11-21       Impact factor: 5.923

Review 8.  Transplantable Melanomas in Hamsters and Gerbils as Models for Human Melanoma. Sensitization in Melanoma Radiotherapy-From Animal Models to Clinical Trials.

Authors:  Martyna Śniegocka; Ewa Podgórska; Przemysław M Płonka; Martyna Elas; Bożena Romanowska-Dixon; Małgorzata Szczygieł; Michał A Żmijewski; Mirosława Cichorek; Anna Markiewicz; Anna A Brożyna; Andrzej T Słominski; Krystyna Urbańska
Journal:  Int J Mol Sci       Date:  2018-04-01       Impact factor: 5.923

9.  In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.

Authors:  Seohyun Kim; Seong A Kim; Gi-Hoon Nam; Yeonsun Hong; Gi Beom Kim; Yoonjeong Choi; Seokyoung Lee; Yuri Cho; Minsu Kwon; Cherlhyun Jeong; Sehoon Kim; In-San Kim
Journal:  J Immunother Cancer       Date:  2021-01       Impact factor: 13.751

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.